Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...
In a report released today, Geoff Meacham from Citi maintained a Buy rating on Eli Lilly & Co (LLY – Research Report). The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback